ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.970
-0.080 (-2.62%)
Apr 3, 2025, 2:57 PM EDT - Market open

ImmunityBio Statistics

Total Valuation

ImmunityBio has a market cap or net worth of $2.53 billion. The enterprise value is $3.16 billion.

Market Cap 2.53B
Enterprise Value 3.16B

Important Dates

The last earnings date was Monday, March 3, 2025, before market open.

Earnings Date Mar 3, 2025
Ex-Dividend Date n/a

Share Statistics

ImmunityBio has 853.44 million shares outstanding. The number of shares has increased by 37.71% in one year.

Current Share Class 853.44M
Shares Outstanding 853.44M
Shares Change (YoY) +37.71%
Shares Change (QoQ) +5.24%
Owned by Insiders (%) 34.64%
Owned by Institutions (%) 10.37%
Float 204.85M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 144.24
Forward PS 20.21
PB Ratio -5.16
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 214.15
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.36

Current Ratio 3.36
Quick Ratio 2.77
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -2.23

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -48.48%
Return on Invested Capital (ROIC) -71.77%
Return on Capital Employed (ROCE) -104.94%
Revenue Per Employee $21,684
Profits Per Employee -$608,182
Employee Count 680
Asset Turnover 0.03
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -43.93% in the last 52 weeks. The beta is -0.15, so ImmunityBio's price volatility has been lower than the market average.

Beta (5Y) -0.15
52-Week Price Change -43.93%
50-Day Moving Average 3.11
200-Day Moving Average 4.07
Relative Strength Index (RSI) 49.03
Average Volume (20 Days) 5,573,184

Short Selling Information

The latest short interest is 59.54 million, so 6.98% of the outstanding shares have been sold short.

Short Interest 59.54M
Short Previous Month 60.93M
Short % of Shares Out 6.98%
Short % of Float 29.07%
Short Ratio (days to cover) 9.03

Income Statement

In the last 12 months, ImmunityBio had revenue of $14.75 million and -$413.56 million in losses. Loss per share was -$0.62.

Revenue 14.75M
Gross Profit 14.75M
Operating Income -344.18M
Pretax Income n/a
Net Income -413.56M
EBITDA -326.63M
EBIT -344.18M
Loss Per Share -$0.62
Full Income Statement

Balance Sheet

The company has $149.81 million in cash and $789.82 million in debt, giving a net cash position of -$640.01 million or -$0.75 per share.

Cash & Cash Equivalents 149.81M
Total Debt 789.82M
Net Cash -640.01M
Net Cash Per Share -$0.75
Equity (Book Value) -488.13M
Book Value Per Share -0.57
Working Capital 129.64M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$391.24 million and capital expenditures -$6.89 million, giving a free cash flow of -$398.12 million.

Operating Cash Flow -391.24M
Capital Expenditures -6.89M
Free Cash Flow -398.12M
FCF Per Share -$0.47
Full Cash Flow Statement

Margins

Gross Margin 100.00%
Operating Margin -2,334.24%
Pretax Margin -2,805.32%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

ImmunityBio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -37.71%
Shareholder Yield -37.71%
Earnings Yield -16.43%
FCF Yield -15.81%

Analyst Forecast

The average price target for ImmunityBio is $11.35, which is 282.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target $11.35
Price Target Difference 282.16%
Analyst Consensus Strong Buy
Analyst Count 5
Revenue Growth Forecast (5Y) 173.00%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

ImmunityBio has an Altman Z-Score of -12.5 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -12.5
Piotroski F-Score 3